expresspharmaJune 12, 2020
Tag: lupin , FDA , Albendazole Tablets
Pharma major Lupin announced that it has received approval for its Albendazole Tablets USP, 200 mg, from the United States Food and Drug Administration (US FDA), to market a generic equivalent of Albenza Tablets, 200 mg, of Impax Laboratories.
Albendazole Tablets USP, 200 mg, are an anthelmintic drug indicated for treatment of:
Parenchymal neurocysticercosis due to active lesions caused by larval forms of the pork tapeworm
Cystic hydatid disease of the liver, lung, and peritoneum, caused by the larval form of the dog tapeworm
Albendazole Tablets USP (RLD: Albenza) had an annual sales of approximately USD 34 million in the US (IQVIA MAT April 2020).
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: